Literature DB >> 991096

Breast cancer--influence of growth rate on prognosis and treatment evaluation: a study based on mastectomy scar recurrences.

A W Pearlman.   

Abstract

The growth rate of a mammary cancer can be calculated when a recurrence appears in the mastectomy scar. Growth rate can, at times, be approximated from the patient's history with reasonable accuracy. Approximately half of breast cancers exhibit rapid growth (tumor doubling time (Td), up to 25 days); one-third grow at an intermediate rate (Td 26 to 75 days) and 15% grow slowly (Td 76 days or longer). Anatomic (TNM) staging does not define a homogeneous patient group in breast cancer. Within each stage, there are rapid, intermediate, and slow-growing tumors. The prognosis varies importantly with the growth rate characteristics of the tumor. Survival is the product of the tumor doubling time and the number of tumor doublings through which the patient lives. Slowly growing and intermediate growth rate tumors are associated with a high percentage of 5-year survivors after mastectomy (between 80 and 100%). Rapidly growing tumors have few 5-year survivors. When survival after mastectomy is measured in the number of tumor doublings, the differences in survival of the three groups tended to disappear, indicating that in this select group of patients with scar recurrence there was no therapeutic advantage in any of the three groups, despite the differences in the survival times. The appreciable number of patients with tumors exhibiting slow or intermediate growth rates, in any series, suggests that the use of the 5-year interval is an inadequate measure of therapeutic response in breast cancer and may actually be misleading.

Entities:  

Mesh:

Year:  1976        PMID: 991096     DOI: 10.1002/1097-0142(197610)38:4<1826::aid-cncr2820380460>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  The Canadian National Breast Screening Study: a clinician's perspective.

Authors:  A A Starreveld
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

2.  Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).

Authors:  Aman P Singh; Dhaval K Shah
Journal:  AAPS J       Date:  2017-04-03       Impact factor: 4.009

3.  Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.

Authors:  H Nakabayashi; M Sakaguchi; J Katsuyama; A Hakuba
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

4.  Breast metastasis from vaginal cancer.

Authors:  Neeraja Chandrasekaran; Daniel Scharifker; George Varsegi; Zoyla Almeida
Journal:  BMJ Case Rep       Date:  2016-07-21

5.  Volume growth rate of acoustic neurinomas.

Authors:  E M Laasonen; H Troupp
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

Review 6.  Timing and Delays in Breast Cancer Evaluation and Treatment.

Authors:  Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2018-07-02       Impact factor: 5.344

Review 7.  The biology and natural history of breast cancer from the screening perspective.

Authors:  L Holmberg; J Pontén; H O Adami
Journal:  World J Surg       Date:  1989 Jan-Feb       Impact factor: 3.352

8.  A simulation model of the natural history of human breast cancer.

Authors:  S Koscielny; M Tubiana; A J Valleron
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

9.  Growth rate of primary breast cancer and prognosis: observations on a 3- to 7-year follow-up in 180 breast cancers.

Authors:  E Galante; G Gallus; A Guzzon; A Bono; G Bandieramonte; S Di Pietro
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

10.  Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.

Authors:  Patricia Tai; Edward Yu; Vincent Vinh-Hung; Gábor Cserni; Georges Vlastos
Journal:  BMC Cancer       Date:  2004-09-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.